295 related articles for article (PubMed ID: 23776587)
41. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
Souglakos J; Philips J; Wang R; Marwah S; Silver M; Tzardi M; Silver J; Ogino S; Hooshmand S; Kwak E; Freed E; Meyerhardt JA; Saridaki Z; Georgoulias V; Finkelstein D; Fuchs CS; Kulke MH; Shivdasani RA
Br J Cancer; 2009 Aug; 101(3):465-72. PubMed ID: 19603024
[TBL] [Abstract][Full Text] [Related]
42. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
43. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
Garcia-Albeniz X; Pericay C; Alonso-Espinaco V; Alonso V; Escudero P; Fernández-Martos C; Gallego R; Gascón P; Castellví-Bel S; Maurel J
Tumour Biol; 2011 Apr; 32(2):417-24. PubMed ID: 21104178
[TBL] [Abstract][Full Text] [Related]
44. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.
Tougeron D; Lecomte T; Pagès JC; Villalva C; Collin C; Ferru A; Tourani JM; Silvain C; Levillain P; Karayan-Tapon L
Ann Oncol; 2013 May; 24(5):1267-73. PubMed ID: 23293113
[TBL] [Abstract][Full Text] [Related]
45. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
46. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.
Chen J; Ye Y; Sun H; Shi G
Cancer Chemother Pharmacol; 2013 Jan; 71(1):265-72. PubMed ID: 23090619
[TBL] [Abstract][Full Text] [Related]
47. Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
Wen F; Tang R; Sang Y; Li M; Hu Q; Du Z; Zhou Y; Zhang P; He X; Li Q
Cancer Sci; 2013 Oct; 104(10):1330-8. PubMed ID: 23822592
[TBL] [Abstract][Full Text] [Related]
48. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis.
Petrelli F; Barni S;
Int J Colorectal Dis; 2012 Aug; 27(8):997-1004. PubMed ID: 22358385
[TBL] [Abstract][Full Text] [Related]
49. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
Vale CL; Tierney JF; Fisher D; Adams RA; Kaplan R; Maughan TS; Parmar MK; Meade AM
Cancer Treat Rev; 2012 Oct; 38(6):618-25. PubMed ID: 22118887
[TBL] [Abstract][Full Text] [Related]
50. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.
Qiu LX; Mao C; Zhang J; Zhu XD; Liao RY; Xue K; Li J; Chen Q
Eur J Cancer; 2010 Oct; 46(15):2781-7. PubMed ID: 20580219
[TBL] [Abstract][Full Text] [Related]
51. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
Behl AS; Goddard KA; Flottemesch TJ; Veenstra D; Meenan RT; Lin JS; Maciosek MV
J Natl Cancer Inst; 2012 Dec; 104(23):1785-95. PubMed ID: 23197490
[TBL] [Abstract][Full Text] [Related]
53. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
Blank PR; Moch H; Szucs TD; Schwenkglenks M
Clin Cancer Res; 2011 Oct; 17(19):6338-46. PubMed ID: 21807639
[TBL] [Abstract][Full Text] [Related]
54. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
[TBL] [Abstract][Full Text] [Related]
55.
Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
[No Abstract] [Full Text] [Related]
56. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
57. Effect of KRAS and BRAF mutations in metastatic colorectal cancer patients: A systematic review and meta-analysis based on tumor sidedness and KRAS subtypes.
Saravani K; Salarzaei M; Parooie F
Hum Antibodies; 2021; 29(4):275-284. PubMed ID: 34334388
[TBL] [Abstract][Full Text] [Related]
58. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
[TBL] [Abstract][Full Text] [Related]
59. Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer.
Tan ES; Fan W; Knepper TC; Schell MJ; Sahin IH; Fleming JB; Xie H
Target Oncol; 2022 Jul; 17(4):483-492. PubMed ID: 35767139
[TBL] [Abstract][Full Text] [Related]
60. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
